Bioretec™

Q3 2026 Results Review

Webcast
November 12, 2026



DESIGN FROM FINLAND®

Commercial Momentum Continues

Commercial Drivers

- Growth across all regions, +85.5%
- US delivering strongest topline quarterly performance of the year
- Where to play, High Value Markets, Repeatable Demand

Key Milestones

- FDA 510K approval : Activa COM cannulated screw
- >500K Activa implants sold
- Transitional Pass Through Payment solidfied through ’28

*(Quarterly yoy comparison period)



Q3 sales: Geographic Split


Net sales by geographical area

EUR 1,000	7–9/2026	7–9/2025	Change	1–9/2026	1–9/2025	Change	1–12/2025
Europe	**384**	227	69.2%	**1,162**	580	100.3%	**887**
The U.S.	**443**	183	142.7%	**1,041**	366	184.1%	**488**
Rest of the world	**501**	306	63.6%	**1,444**	1,843	-21.6%	**2,146**
Total	**1,328**	**715**	**85.5%**	**3,648**	**2,789**	**30.8%**	**3,522**

YTD Performance


Jan-Sep 2026 business performance

EURk



Jan-Sep 2025 business performance

EURk



Key Figures

(EURk)	Q3 2026	Q3 2025	YoY	QoQ
Net Sales	**1,328**	715	+85.5%	+20.7%
Adjusted sales margin[1]	**68.7%**	59.4%		
EBITDA	**-1,746**	-1,768	+1.24%	+22.4%
Cash and cash equivalents	**9,251**	7,263		

[1] Adjusted sales margin includes net sales of implants deducted by related sales of cost in accordance with industry practices

Near Term Product Launches: Path to Growth

Activa™ Headless

Approved

FDA 510(k) Pending



Sizes: 3.5 - 4.5 mm

Length: 20–90 mm

TAM: ~$0.5B

Target: Trauma

RemeOs™ FT Screw

FDA 510(k) Path



Sizes: 3.5 – 4.0 mm

Length: 24 – 50 mm


TAM: ~$1.4B

Target: Trauma

BREAKTHROUGH DEVICE

RemeOs™ DrillPin

Trials Enrolling



Market Disruption

- Self-drilling (No K-wire)
- 850K Hammertoe Surgeries
- Eliminates pin tract infections

BREAKTHROUGH DEVICE

3 Near Term Approvals position Bioretec for Market Leadership

Source: Global Data report 2023, Orthoworld report 2024, Verified Market Reports 2024, Company Information

Bioretec

Strategic Priorities & Financial Targets for 2026–2028

Industry Leading Innovation

Demonstrate industry leading innovation, clinical evidence generation, and **commercial scale** by progressing a strong R&D pipeline and introducing at least **one new product or indication every 12–18 months**, reflected by sustained R&D investments.

World Class Clinical and Economic Evidence Generation

Build strong market presence and solidify our commercial position in the U.S. through **direct distribution channels**, targeted Key Opinion Leader engagement strategies, and high-impact training and education.

Global Excellence in Commercialization Generation

Upgrade our OUS commercial strategy through updated distribution partner selections with rigorous and clear commercial targets and a focused effort on **RemeOs™ launches in high value markets**. Establish RemeOs as the leading **metal alloy absorbable solution** in the orthopedic implant market **globally.**

Financial Targets

- Reach **net sales *exceeding* EUR 10 million** by the end of the year 2028
- Maintain an **average sales margin exceeding 70%** during the strategy period

The financial targets are dependent on the necessary capital infusions required to grow in key markets like the U.S. and currently do not reflect the opportunity for acceleration through key partnerships.